The $7 billion contracts secure Boeing's production lines for nearly ten years, creating sustained demand throughout the entire supply chain ecosystem.
The Pentagon's massive investment signals a broader push to modernise military aviation capabilities, potentially benefiting the entire defense sector.
These companies provide highly specialised components that are difficult to replace, giving them strong positioning as production ramps up.
This basket's total market capitalisation is $1.01T and is anchored by several large-cap constituents, likely giving a relatively stable, lower-risk profile.
BA: $138.67B
LMT: $104.69B
RTX: $230.81B
The Pentagon's $7 billion award to Boeing for Apache helicopters and Pegasus tankers signals sustained investment in military aviation modernisation. This creates a ripple effect throughout the defense supply chain, benefiting not just Boeing but also the specialized suppliers and subcontractors integral to these advanced aircraft programmes.
This group captures companies across the entire defense aviation ecosystem - from prime contractors to critical component suppliers. The contracts secure production lines for nearly a decade, offering potential revenue stability. These are specialized firms providing everything from advanced avionics to composite materials.
Each company was handpicked based on their direct involvement in Boeing's programs or their critical role in the broader military aviation supply chain. Professional analysts identified these firms as positioned to benefit from the production ramp-up, from engine suppliers to aerostructure manufacturers.
The Pentagon has awarded Boeing over $7 billion in contracts to produce Apache helicopters and Pegasus tankers, signaling a major investment in military aviation. This creates a potential ripple effect, boosting not only Boeing but also the key suppliers and subcontractors integral to these advanced aircraft programs.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Read Full Insight
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Published on November 26
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
On average, analysts expect assets in this group to grow 8.79% over the next year.
14 of 16 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+8.79%
